Studies using the Caki-1 cell line, a human ccRCC model, demonstrate that restoration of VHL function after mutation leads to a decrease in tumorigenicity, which can also be considered a potential therapeutic approach [11]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.